Abraxas Pharma

Abraxis BioScience was a leading biopharmaceutical company primarily recognized for its innovative nab (nanoparticle albumin-bound) technology platform. This proprietary platform leverages the natural transport properties of albumin to deliver therapeutic agents directly to tumor sites, enhancing efficacy while reducing systemic toxicity. The company's flagship product, Abraxane (nab-paclitaxel), achieved significant clinical and commercial success, receiving FDA approval for metastatic breast cancer, non-small cell lung cancer, and advanced pancreatic cancer. Founded by Dr. Patrick Soon-Shiong, Abraxis BioScience was acquired by Celgene Corporation in 2010 for approximately $2.9 billion plus contingent value rights. Following Celgene's acquisition by Bristol Myers Squibb in 2019, the company's assets and technology continue to be a core part of the BMS oncology portfolio.